Join us for the PolTREG H1 2024 financial results webinar!

2024-09-11

Join us for the PolTREG H1 2024 financial results webinar!

We are pleased to invite you to our upcoming webinar, which will present the financial results for H1 2024 and PolTREG’s development plans.

Join us on Friday, September 13, 2024, at 2:00 PM CEST, where you will hear directly from our company’s management:

Piotr Trzonkowski, Co-founder and CEO

Mariusz Jablonski, Member of the Management Board

Paulina Kocenko-Merks, Member of the Management Board, CFO

Dan Shelly, Chief Business Development Officer

Karol Ptach, Director of Manufacturing Operations

The webinar will be conducted in Polish and partially in English.

See other news

2024-09-26

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

See

2024-09-16

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

See

2024-09-09

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

See

2024-07-24

The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.

See

2024-06-25

PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

See

2024-06-24

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

See

2024-06-13

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

See

2024-05-14

PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered

See

Join us for the PolTREG H1 2024 financial results webinar!

See other news

About Us

Our Science

Patients